Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Psychedelic trip sitting, dosages and intensities

Supplementing clinical studies with anecdotal reports

Bibliographic Data

ID4652089
AuthorsLiam B Engel (0000-0001-8030-7210, Royal Botanic Garden Sydney, corresponding author), Sascha Thal (0000-0001-9028-9335, Murdoch University), Stephen J Bright (0000-0002-9001-032X, Edith Cowan University), Mitchell Low (0000-0002-7928-0089, Western Sydney University)
Year2024
Publication date2024-07-17
Open AccessYes
TypeARTICLE
VenueJournal of Psychedelic Studies (JOURNAL)
Journal identifiersISSN: 2559-9283 • E-ISSN: 2559-9283
PublisherAkademiai Kiado Zrt (PUBLISHER)
DOI10.1556/2054.2024.00377
OpenAlexW4400732567
LanguageEN
Citations received1
References cited27

Background and aimsOnline communities provide insights into psychedelic consumption, assisting in identification of trends, informing both harm reduction provisions and clinical research. This study extracts forum data on psychedelic substances, dosages, and administration routes, categorising and analysing self-reported consumption to inform care services and guide clinical work with psychedelics.MethodsPosts (n = 660) from online psychedelic forums (The Shroomery and DMT Nexus) on 'trip sitting' were analysed. Using a Delphi-style expert panel review facilitated by LE, we created drug weight and intensity charts (threshold, light, common, strong and heavy dosages) for psychedelics discussed in these posts. The psychedelic substance, dosage intensity and route of administration [ROA] (smoked/vaporised, oral, injected, insufflated and undisclosed) frequencies and exploring correlations with perceived need for assistance from a psychedelic carer were mapped and correlated with perceived need for psychedelic care.ResultsPsychedelics appearing in our data were 5-MeO-DMT, ayahuasca, changa, LSA, LSD and psilocybin. There was greater commonality between clinical studies and 'common' doses determined through the Delphi method, for more extensively researched substances like LSD and psilocybin. Many posts indicated opinions that psychedelic care was unnecessary or optional for consumers, particularly for LSD and LSA. 5-MeO-DMT was strongly associated with a perceived need for care. A correlation was identified between greater psychedelic purity, dosage intensity, and a perceived need for care. Oral administration, the most common ROA, showed lower dosage intensity.ConclusionMore research is needed to understand factors influencing psychedelic care practices. Educational information, emphasizing risk management strategies, should be provided to psychedelic consumers, emphasising psychedelic products and administration methods more likely to be dosed at a strong or heavy intensity

Delphi method · Dose · Hallucinogen · Mescaline · Psilocybin · Biochemical Analysis and Sensing Techniques · Chemical synthesis and alkaloids · Medicine · Psychedelics and Drug Studies · Psychology · Pharmacology

  • The Trouble With Psychedelic Cacti

    Open Access•Liam B Engel, Mitchell Low•Contemporary Drug Problems•2025

  • Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

    Open Access•Roland R Griffiths, Matthew W Johnson et al.•Journal of Psychopharmacology•2016

  • Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction

    Open Access•Matthew W Johnson, Albert Garcia-Romeu et al.•Journal of Psychopharmacology•2014

  • The Delphi method as a research tool

    Open Access•Chitu Okoli, Suzanne D Pawlowski•Information & Management•2004

  • Inclusion of people of color in psychedelic-assisted psychotherapy

    Open Access•Timothy I Michaels, Jennifer Purdon et al.•BMC Psychiatry•2018

  • Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

    Charles S Grob, Alicia Danforth et al.•Archives of General Psychiatry•2011

  • Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

    Open Access•A K Davis, Frederick S Barrett et al.•JAMA Psychiatry•2021

  • Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer

    Open Access•Stephen Ro, Stephen Ross et al.•Journal of Psychopharmacology•2016

  • Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

    Open Access•Guy M Goodwin, Scott T Aaronson et al.•New England Journal of Medicine•2022

  • Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder

    Francisco Moreno, Francisco A Moreno et al.•The Journal of Clinical Psychiatry•2006

  • Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression

    Open Access•Fernanda Palhano-Fontes, Dayanna Barreto et al.•Psychological Medicine•2019

  • Hallucinogens

    Open Access•David E Nichols•Pharmacology & Therapeutics•2004

  • Psilocybin with psychological support for treatment-resistant depression

    Open Access•Robin L Carhart-Harris, Mark Bolstridge et al.•The Lancet Psychiatry•2016

  • Psychedelics

    Open Access•David E Nichols•Pharmacological Reviews•2016

  • Trial of Psilocybin versus Escitalopram for Depression

    Open Access•Robin Carhart-Harris, Robin Carhart‐Harris et al.•New England Journal of Medicine•2021

  • Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases

    Open Access•Peter Gasser, Dominique Holstein et al.•The Journal of Nervous and Mental…•2014

  • Psilocybin-assisted treatment for alcohol dependence

    Open Access•Michael P Bogenschutz, Alyssa A Forcehimes et al.•Journal of Psychopharmacology•2015

  • The Use of LSD-25 in the Treatment of Alcoholism and Other Psychiatric Problems

    J Ross MacLean, Doune Macdonald et al.•Quarterly Journal of Studies on…•1961

  • A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

    Open Access•Johannes T Reckweg, C J Van Leeuwen et al.•Frontiers in Psychiatry•2023

  • Sober sitter or coconsumer? Psychedelics, online forums and preferences for interpersonal interactions

    Sascha Thal, Liam B Engel et al.•Addiction Research & Theory•2022

  • The Origins of Inebriation

    Open Access•Elisa Guerra Doce•Journal of Archaeological Method…•2014

  • Psychedelic Forum Member Preferences for Carer Experience and Consumption Behavior

    Open Access•Liam B Engel, Sascha Thal et al.•Contemporary Drug Problems•2022

  • Presence, Trust, and Empathy

    Open Access•Sascha Thal, Liam B Engel et al.•Journal of Humanistic Psychology•2022

  • Use of psilocybin ("mushrooms") among US adults

    Open Access•R Andrew Yockey, Andrew Yockey et al.•Journal of Psychedelic Studies•2021

  • Long-lasting analgesic effect of the psychedelic drug changa

    Open Access•Genís Ona, Sebastián Peña Troncoso et al.•Journal of Psychedelic Studies•2019

Citations per year1
Citation span2025 - 2025 (1)
Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae